Cite
HARVARD Citation
Aranow, C. et al. (n.d.). FRI0305 Phase 2 trial of induction therapy with anti-cd20 (RITUXIMAB) followed by maintenance therapy with anti-baff (BELIMUMAB) in patients with active lupus nephritis. Annals of the rheumatic diseases. p. 690. [Online].